商品情報にスキップ
1 2

Lundbeck A/S

通常価格 ¥1,144 JPY
通常価格 セール価格 ¥1,144 JPY
セール 売り切れ
税込み。
書籍サイズ
ページ数

The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999. The focus of the case is about valuation, but a number of other issues arise for discussion: The company's strategy in deciding to make the IPO What the considerations were for the management and shareholder in agreeing on the issuing price and timing The number of shares to be sold, where they would be sold, and how the after-market should be developed and maintained Lundbeck is a medium-sized pharmaceutical company based in Denmark. It is specialized in the research and development, manufacture, marketing and sale of drugs for the treatment of psychological and neurological diseases and disorders. Group sales for 1998 were DKK 3.2 billion of which its principal product, citalopram accounted for DKK 2.1 billion or two-thirds of the total. The company has production facilities in Denmark and the U.K. Most R&D is carried out by the company itself, or through licensing, and from strategic alliances with others having expertise in a specific area. Some 475 scientists and technicians are employed in R&D out of a total 2,286 full-time employees in the company. Until the IPO, the Lundbeck Foundation was the sole shareholder. The IPO would put about 20% of the shares on the market in a so-called Global Offering. A listing of the shares would be made on the Copenhagen stock market.

【書誌情報】

ページ数:12ページ

サイズ:A4

商品番号:HBSP-IN1086

発行日:2000/12/1

登録日:2016/7/11

1 3